In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships for public biotech companies, that was born out of observations and conversations with many public, non-revenue generating biotech companies over the years.
Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including,
In this whitepaper, you’ll discover China and Japan are combining to invigorate the deal making landscape in Asia, even though their biopharma ecosystem dynamics are markedly different. Regardless, they are affecting deal making strategies globally.
At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients. Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.
Emerging biopharma companies with promising lead candidates in late-stage trials are often faced with a fundamental decision: go-it-alone (self-commercialize) or secure a strategic partner to support development and commercialization.
Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies.
One of the most important elements of successful deal discussions is establishing your credibility to a potential partner. This can be done in a multitude of ways
As it is often necessary to structure creative deals with deferred and/or ongoing value delivered to the seller, an important but frequently overlooked component of the deal process is to position your company as the ideal partner for the acquired asset.
Maintaining Deal Momentum in the Summertime CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process